SHANGGONG

Shanggong, a high-tech enterprise in the AI medical field, was founded in 2014 by seasoned professionals from the medical industry. Through its cloud-based intelligent diagnosis product for fundus imaging—“Shanggong Huiyan,” Shanggong provides screening services for common fundus diseases. Its main product, “Huiyan Diabetic Retinopathy (SG-DR),” offers diabetic retinopathy screening services for endocrinology or primary internal medicine departments. Based on the needs of fundus imaging screening services and clinical applications, Shanggong has further developed the diabetes and complications smart management platform “SG-DCSmart,” providing chronic disease management services to primary healthcare institutions. The company’s technology is internationally leading and features extensive compatibility. In multiple international competitions, the company has achieved one first place and several top-three finishes. Its products are compatible with over 20 brands of fundus cameras and can be applied across all levels of medical institutions, including tertiary, secondary, and primary care facilities. The company serves more than 600 medical institutions, including over 300 tertiary hospitals, serving more than 1 million patients, with over 2 million fundus images processed. The company has become a long-term partner of major enterprises such as Merck Sharp & Dohme (MSD), Bayer, Abbott, Canon, and Kanghong Pharmaceuticals, and has established strategic partnerships with health commissions of certain provinces and cities, the National Technical Guidance Group for Blindness Prevention, and the Chinese Society for Microcirculation.